Identification

Name
Romidepsin
Accession Number
DB06176
Type
Small Molecule
Groups
Approved, Investigational
Description

Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.

Structure
Thumb
Synonyms
  • chromodax
External IDs
FK 228 / FK-228 / FK228 / FR 901228 / FR-901228 / FR901228 / NSC 630176 / NSC-630176 / NSC630176
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IstodaxKitGloucester Pharmaceuticals, Inc.2010-01-042016-10-13Us
IstodaxKitCelgene2010-01-04Not applicableUs
IstodaxKit; Powder, for solution10 mgIntravenousCelgene2014-02-05Not applicableCanada
IstodaxKitCelgene2010-01-04Not applicableUs
International/Other Brands
istodax
Categories
UNII
CX3T89XQBK
CAS number
128517-07-7
Weight
Average: 540.69
Monoisotopic: 540.207627243
Chemical Formula
C24H36N4O6S2
InChI Key
OHRURASPPZQGQM-QDBHDZETSA-N
InChI
InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7-,16-6-/t15-,17-,19-,20+/m1/s1
IUPAC Name
(1S,4S,7Z,10S,21R)-7-ethylidene-6,9,19,22-tetrahydroxy-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricosa-5,8,16,19,22-pentaen-3-one
SMILES
[H]\C(C)=C1\N=C(O)[[email protected]@]2([H])CSSCCC([H])=C([H])[[email protected]]([H])(CC(O)=N[[email protected]]([H])(C(C)C)C(O)=N2)OC(=O)[[email protected]@]([H])(N=C1O)C(C)C

Pharmacology

Indication

For the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Romidepsin is a prodrug, where it becomes active once taken up into the cell. The active metabolite has a free thiol group, which interacts with zinc ions in the active site of class 1 and 2 HDAC enzymes, resulting in inhibition of its enzymatic activity. Certain tumors have over expressed HDACs and downregulated/mutated histone acetyltransferases. This imbalance of HDAC relative to histone acetyltransferase can lead to a decrease in regulatory genes, ensuing tumorigenesis. Inhibition of HDAC may restore normal gene expression in cancer cells and result in cell cycle arrest and apoptosis.

TargetActionsOrganism
AHistone deacetylase 1
antagonist
inhibitor
Human
AHistone deacetylase 2
antagonist
inhibitor
Human
NHistone deacetylase 4
inhibitor
Human
NHistone deacetylase 6
inhibitor
Human
UMultidrug resistance-associated protein 1Not AvailableHuman
Absorption

Romidepsin exhibited linear pharmacokinetics at standard doses.

Volume of distribution

44.5L

Protein binding

Highly protein bound in plasma (92%-94%)

Metabolism

Romidepsin undergoes extensive hepatic metabolism in vitro primarily by CYP3A4 with minor contribution from CYP3A5, CYP1A1, CYP2B6 and CYP2C19.

Route of elimination
Not Available
Half life

Approximately 3 hours

Clearance

8.4L/h

Toxicity

Risk factor D in pregnancy. It is not known if romidepsin is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. The majority of patients receiving romidepsin experience nausea, vomiting, and anorexia.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe metabolism of Romidepsin can be decreased when combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Romidepsin can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Romidepsin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Romidepsin.Experimental
AfatinibThe serum concentration of Romidepsin can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Romidepsin can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Romidepsin can be decreased when it is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Romidepsin can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Romidepsin can be increased when it is combined with Alfentanil.Approved, Illicit
AmantadineThe serum concentration of Romidepsin can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Romidepsin can be increased when it is combined with Aminohippuric acid.Approved, Investigational
AmiodaroneThe serum concentration of Romidepsin can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Romidepsin can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Romidepsin can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Romidepsin can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Romidepsin can be increased when it is combined with Amsacrine.Approved
AprepitantThe serum concentration of Romidepsin can be increased when it is combined with Aprepitant.Approved, Investigational
ArmodafinilThe metabolism of Romidepsin can be decreased when combined with Armodafinil.Approved, Investigational
AstemizoleThe serum concentration of Romidepsin can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Romidepsin can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Romidepsin can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Romidepsin can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Romidepsin can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Romidepsin can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Romidepsin can be increased when it is combined with Azithromycin.Approved
BenzocaineThe serum concentration of Romidepsin can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Romidepsin can be increased when it is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Romidepsin.Approved, Investigational
BiperidenThe serum concentration of Romidepsin can be increased when it is combined with Biperiden.Approved, Investigational
BoceprevirThe serum concentration of Romidepsin can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Romidepsin can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Romidepsin can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Romidepsin can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Romidepsin can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Romidepsin can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Romidepsin can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Romidepsin.Approved
CaffeineThe serum concentration of Romidepsin can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Romidepsin can be increased when it is combined with Canagliflozin.Approved
Candesartan cilexetilThe serum concentration of Romidepsin can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Romidepsin can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Romidepsin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Romidepsin can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Romidepsin can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Romidepsin can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Romidepsin can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Romidepsin can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Romidepsin can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Romidepsin can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Romidepsin can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
CholecalciferolThe metabolism of Romidepsin can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Romidepsin can be increased when it is combined with Cholesterol.Experimental, Investigational
Cholic AcidThe serum concentration of Romidepsin can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Romidepsin can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Romidepsin can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Romidepsin can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Romidepsin can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Romidepsin can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Romidepsin can be decreased when combined with Clemastine.Approved
ClofazimineThe serum concentration of Romidepsin can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Romidepsin can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClopidogrelThe metabolism of Romidepsin can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe metabolism of Romidepsin can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Romidepsin can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Romidepsin can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Romidepsin can be increased when it is combined with Colforsin.Experimental, Investigational
ConivaptanThe serum concentration of Romidepsin can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Romidepsin can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Romidepsin.Approved, Investigational
CyclosporineThe metabolism of Romidepsin can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Romidepsin.Experimental
DabrafenibThe serum concentration of Romidepsin can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Romidepsin can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Romidepsin can be increased when it is combined with Dactinomycin.Approved
DarunavirThe serum concentration of Romidepsin can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Romidepsin can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Romidepsin can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Romidepsin can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Romidepsin can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Romidepsin can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Romidepsin.Approved
DesloratadineThe serum concentration of Romidepsin can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Romidepsin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Romidepsin can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Romidepsin can be increased when it is combined with Diclofenac.Approved, Vet Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Romidepsin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Romidepsin.Approved
DihydroergotamineThe metabolism of Romidepsin can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Romidepsin can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Romidepsin can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Romidepsin.Approved, Investigational
DoxazosinThe serum concentration of Romidepsin can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Romidepsin can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Romidepsin can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Romidepsin can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Romidepsin can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Romidepsin can be decreased when combined with Dronedarone.Approved
EfavirenzThe metabolism of Romidepsin can be decreased when combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Romidepsin can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Romidepsin can be increased when it is combined with Enalapril.Approved, Vet Approved
EnasidenibThe serum concentration of Romidepsin can be increased when it is combined with Enasidenib.Approved
ErgonovineThe serum concentration of Romidepsin can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Romidepsin can be increased when it is combined with Ergotamine.Approved
ErythromycinThe metabolism of Romidepsin can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe metabolism of Romidepsin can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Romidepsin can be decreased when combined with Esomeprazole.Approved, Investigational
EstramustineThe serum concentration of Romidepsin can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Romidepsin can be decreased when it is combined with Estriol.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Romidepsin can be decreased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Romidepsin can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Romidepsin can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Romidepsin can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Romidepsin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Romidepsin can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Romidepsin can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe metabolism of Romidepsin can be decreased when combined with Fluconazole.Approved
FluoxetineThe serum concentration of Romidepsin can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Romidepsin can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Romidepsin can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Romidepsin can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe metabolism of Romidepsin can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Romidepsin can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Romidepsin can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Romidepsin can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Romidepsin can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Romidepsin can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Romidepsin can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Romidepsin can be increased when it is combined with Genistein.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Romidepsin.Experimental
GlecaprevirThe serum concentration of Romidepsin can be increased when it is combined with Glecaprevir.Approved
GlyburideThe serum concentration of Romidepsin can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Romidepsin can be increased when it is combined with Glycerin.Approved, Investigational
Gramicidin DThe serum concentration of Romidepsin can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Romidepsin can be increased when it is combined with Grepafloxacin.Investigational, Withdrawn
HaloperidolThe serum concentration of Romidepsin can be increased when it is combined with Haloperidol.Approved
HydrocortisoneThe serum concentration of Romidepsin can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
ImatinibThe metabolism of Romidepsin can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Romidepsin can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Romidepsin can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Romidepsin can be increased when it is combined with Indomethacin.Approved, Investigational
IsavuconazoniumThe metabolism of Romidepsin can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Romidepsin can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Romidepsin can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Romidepsin can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Romidepsin can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Romidepsin can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Romidepsin can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Romidepsin can be increased when it is combined with Ketoconazole.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Romidepsin.Experimental
LansoprazoleThe serum concentration of Romidepsin can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Romidepsin can be increased when it is combined with Lapatinib.Approved, Investigational
LevofloxacinThe serum concentration of Romidepsin can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Romidepsin can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Romidepsin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Romidepsin can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Romidepsin can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Romidepsin can be increased when it is combined with Lisinopril.Approved, Investigational
LobeglitazoneThe metabolism of Romidepsin can be decreased when combined with Lobeglitazone.Approved, Investigational
LomitapideThe serum concentration of Romidepsin can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Romidepsin can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Romidepsin can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Romidepsin can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Romidepsin can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Romidepsin can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Romidepsin can be increased when it is combined with Luliconazole.Approved
MaprotilineThe serum concentration of Romidepsin can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Romidepsin can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Romidepsin can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Romidepsin can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Romidepsin can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Romidepsin can be increased when it is combined with Methadone.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Romidepsin.Experimental
MetoprololThe serum concentration of Romidepsin can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Romidepsin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Romidepsin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Romidepsin can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Romidepsin can be increased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Romidepsin can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Romidepsin can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Romidepsin can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Romidepsin can be decreased when combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Romidepsin can be increased when it is combined with Morphine.Approved, Investigational
NaltrexoneThe serum concentration of Romidepsin can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Romidepsin can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Romidepsin can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Romidepsin can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Romidepsin can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Romidepsin can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Romidepsin can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Romidepsin can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Romidepsin can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Romidepsin can be decreased when combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Romidepsin can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Romidepsin can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Romidepsin can be increased when it is combined with Nitrendipine.Approved, Investigational
NorethisteroneThe serum concentration of Romidepsin can be decreased when it is combined with Norethisterone.Approved
OlaparibThe metabolism of Romidepsin can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Romidepsin.Experimental, Investigational
OmeprazoleThe serum concentration of Romidepsin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Romidepsin can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Romidepsin.Approved
P-NitrophenolThe serum concentration of Romidepsin can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Romidepsin.Approved, Vet Approved
PalbociclibThe serum concentration of Romidepsin can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Romidepsin can be increased when it is combined with Palmitic Acid.Approved, Experimental
PantoprazoleThe serum concentration of Romidepsin can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Romidepsin can be increased when it is combined with Paroxetine.Approved, Investigational
PentobarbitalThe serum concentration of Romidepsin can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Romidepsin can be increased when it is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Romidepsin.Experimental
PhenobarbitalThe serum concentration of Romidepsin can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Romidepsin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Romidepsin can be increased when it is combined with Pibrentasvir.Approved
PimozideThe serum concentration of Romidepsin can be increased when it is combined with Pimozide.Approved
Platelet Activating FactorThe serum concentration of Romidepsin can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Romidepsin can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Romidepsin can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Romidepsin can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Romidepsin can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Romidepsin can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimidoneThe serum concentration of Romidepsin can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Romidepsin can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Romidepsin can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Romidepsin can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Romidepsin can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Romidepsin can be increased when it is combined with Propranolol.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Romidepsin.Experimental
ProtriptylineThe serum concentration of Romidepsin can be increased when it is combined with Protriptyline.Approved
QuazepamThe serum concentration of Romidepsin can be increased when it is combined with Quazepam.Approved, Illicit
QuercetinThe serum concentration of Romidepsin can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Romidepsin can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidineThe serum concentration of Romidepsin can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Romidepsin can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Romidepsin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Romidepsin can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Romidepsin can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Romidepsin can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Romidepsin can be decreased when it is combined with Reserpine.Approved, Investigational
RifabutinThe serum concentration of Romidepsin can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Romidepsin can be increased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Romidepsin can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Romidepsin can be increased when it is combined with Rilpivirine.Approved
RitonavirThe serum concentration of Romidepsin can be increased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Romidepsin can be increased when it is combined with Rolapitant.Approved
SaquinavirThe serum concentration of Romidepsin can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Romidepsin can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Romidepsin can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Romidepsin can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Romidepsin can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Romidepsin can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Romidepsin can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Romidepsin can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Romidepsin can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Romidepsin can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Romidepsin can be increased when it is combined with Spironolactone.Approved
StaurosporineThe serum concentration of Romidepsin can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Romidepsin can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Romidepsin can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Romidepsin can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Romidepsin can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Romidepsin can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Romidepsin can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Romidepsin can be increased when it is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe serum concentration of Romidepsin can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Romidepsin can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Romidepsin can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Romidepsin can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Romidepsin can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Romidepsin can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Romidepsin can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Romidepsin can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Romidepsin can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Romidepsin can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Romidepsin can be increased when it is combined with Testosterone.Approved, Investigational
ThiotepaThe metabolism of Romidepsin can be decreased when combined with Thiotepa.Approved
TicagrelorThe serum concentration of Romidepsin can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Romidepsin can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Romidepsin can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Romidepsin can be increased when it is combined with Tolvaptan.Approved
TopiramateThe metabolism of Romidepsin can be decreased when combined with Topiramate.Approved
TranylcypromineThe metabolism of Romidepsin can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Romidepsin.Approved, Investigational
TrazodoneThe serum concentration of Romidepsin can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Romidepsin can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Romidepsin can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Romidepsin can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Romidepsin can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Romidepsin can be increased when it is combined with Troleandomycin.Approved
VelpatasvirThe serum concentration of Romidepsin can be increased when it is combined with Velpatasvir.Approved
VenlafaxineThe metabolism of Romidepsin can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Romidepsin can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Romidepsin can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Romidepsin can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Romidepsin can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Romidepsin can be increased when it is combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Romidepsin can be increased when it is combined with Voxilaprevir.Approved
WarfarinRomidepsin may increase the anticoagulant activities of Warfarin.Approved
ZimelidineThe serum concentration of Romidepsin can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Romidepsin can be decreased when combined with Ziprasidone.Approved
ZucapsaicinThe metabolism of Romidepsin can be decreased when combined with Zucapsaicin.Approved
Food Interactions
  • Avoid grapefruit juice.

References

Synthesis Reference

Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, Okuhara M: FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994 Mar;47(3):301-10. Pubmed.

General References
  1. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011 Aug;64(8):525-31. doi: 10.1038/ja.2011.35. Epub 2011 May 18. [PubMed:21587264]
  2. Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS: Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015 Oct 16;5:e357. doi: 10.1038/bcj.2015.83. [PubMed:26473529]
External Links
KEGG Drug
D06637
PubChem Compound
57515973
PubChem Substance
310264861
ChemSpider
28499157
ChEBI
61080
ChEMBL
CHEMBL1998981
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Romidepsin
ATC Codes
L01XX39 — Romidepsin
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (610 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentHistologically Proven Extranodal NKTcell Lymphoma1
1Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
1Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
1Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Peripheral T-Cell Lymphoma (PTCL)1
1Active Not RecruitingTreatmentMalignant Lymphomas1
1CompletedNot AvailableMalignancies, Hematologic / Malignant Lymphomas2
1CompletedTreatmentBlastic Phase Chronic Myelogenous Leukemia / Childhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Chronic Myelogenous Leukemia / Childhood Craniopharyngioma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Spinal Cord Neoplasm / Childhood Supratentorial Ependymoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma / Refractory Chronic Lymphocytic Leukemia / Relapsing Chronic Myelogenous Leukemia / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentLeukemias / Malignant Lymphomas1
1CompletedTreatmentMalignant Lymphomas1
1CompletedTreatmentMalignant Neoplasm of Pancreas1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentTumors, Solid / Virally Mediated Cancers and Liposarcoma1
1RecruitingTreatmentAdult Mixed Glioma / Adult Pineal Gland Astrocytoma / Adult Solid Neoplasm / AIDS Related Immunoblastic Lymphoma / AIDS-Related Burkitt Lymphoma / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-Related Hodgkin Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-Related Primary Central Nervous System Lymphoma / Gliomas / Lymphoma, AIDS Related / Malignant Lymphomas / Metastatic Malignant Solid Neoplasm / Metastatic Solid Neoplasm / Neuroendocrine Neoplasms / Recurrent Adult Brain Neoplasm / Recurrent Adult Soft Tissue Sarcoma / Recurrent Bladder Carcinoma / Recurrent Breast Carcinoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Colorectal Carcinoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Head and Neck Carcinoma / Recurrent Lung Carcinoma / Recurrent Malignant Solid Neoplasm / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Recurrent Melanoma / Recurrent Pancreatic Carcinoma / Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Prostate Carcinoma / Recurrent Solid Neoplasm / Recurrent Thyroid Gland Carcinoma / Refractory Chronic Lymphocytic Leukemia / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma / Renal Cell Carcinoma Recurrent / Stage III Breast Cancer / Stage III Colorectal Cancer / Stage III Colorectal Cancer AJCC v7 / Stage III Cutaneous Melanoma AJCC v7 / Stage III Lung Cancer / Stage III Lung Cancer AJCC v7 / Stage III Pancreatic Cancer / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage III Prostate Cancer / Stage III Renal Cell Cancer / Stage III Soft Tissue Sarcoma / Stage III Soft Tissue Sarcoma AJCC v7 / Stage IIIA Breast Cancer / Stage IIIA Colorectal Cancer / Stage IIIA Colorectal Cancer AJCC v7 / Stage IIIA Cutaneous Melanoma AJCC v7 / Stage IIIA Skin Melanoma / Stage IIIB Breast Cancer / Stage IIIB Colorectal Cancer / Stage IIIB Colorectal Cancer AJCC v7 / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Skin Melanoma / Stage IIIC Breast Cancer / Stage IIIC Colorectal Cancer / Stage IIIC Colorectal Cancer AJCC v7 / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Skin Melanoma / Stage IV Breast Cancer / Stage IV Colorectal Cancer / Stage IV Colorectal Cancer AJCC v7 / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Lung Cancer / Stage IV Lung Cancer AJCC v7 / Stage IV Pancreatic Cancer / Stage IV Pancreatic Cancer AJCC v6 and v7 / Stage IV Prostate Cancer / Stage IV Renal Cell Cancer / Stage IV Skin Melanoma / Stage IV Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma AJCC v7 / Stage IVA Colorectal Cancer / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer / Stage IVB Colorectal Cancer AJCC v7 / Stages III Skin Melanoma / Unresectable Solid Neoplasm1
1RecruitingTreatmentColorectal Cancers1
1RecruitingTreatmentCutaneous Lymphomas / Malignant Lymphomas / T-Cell Lymphomas1
1RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL)2
1RecruitingTreatmentHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements / MYC Positive / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Hodgkin Lymphoma / Refractory Mantle Cell Lymphoma / Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma1
1RecruitingTreatmentHodgkins Disease (HD) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, T-Cell, Cutaneous / Lymphoma, T-Cell, Peripheral1
1RecruitingTreatmentMalignant Lymphomas / Relapsed/Refractory T-cell Lymphomas1
1RecruitingTreatmentRecurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome1
1TerminatedTreatmentCutaneous T-Cell Lymphoma (CTCL) / Mycosis Fungoides (MF) / Neoplasms1
1WithdrawnTreatmentCTCL / PTCL1
1, 2Active Not RecruitingTreatmentCancer, Breast / Triple-Negative Breast Cancer (TNBC)1
1, 2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2Active Not RecruitingTreatmentLymphoma, T-Cell, Peripheral1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentRelapsed or Refractory / Relapsed or Refractory B- / T-Cell Lymphomas1
1, 2CompletedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Recurrent Adult Brain Tumor1
1, 2CompletedTreatmentLung Cancers / Metastatic Cancers1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentPeripheral T Cell Lymphoma (PTCL)1
1, 2Not Yet RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL) / Lymphoid Haematopoietic / Neoplasms, Malignant / Refractory peripheral cutaneous T-cell lymphoma1
1, 2Not Yet RecruitingTreatmentT-Cell Lymphomas1
1, 2RecruitingTreatmentALK- Anaplastic Large Cell Lymphoma (ALCL) / ALK- Anaplastic Largecell Lymphoma (ALCL) / Angioimmunoblastic T-cell Lymphoma (AITL) / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS) / PTCL-NOS1
1, 2RecruitingTreatmentCutaneous T-Cell Lymphoma (CTCL) / Peripheral T-Cell Lymphoma (PTCL) / T-Large Granulocytic Leukemia / T-Lymphoblastic Leukemia/Lymphoma / T-Prolymphocytic Leukemia1
1, 2RecruitingTreatmentLymphoid Malignancies / Lymphoma, Hodgkins / Malignant Lymphomas / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentLymphoid Malignancies / Lymphoma, Hodgkins / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1
1, 2TerminatedTreatmentHER2-Negative Breast Cancer / Inflammatory carcinoma of the breast / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
1, 2TerminatedTreatmentLymphoma, Hodgkins / Mature T-cell Lymphoma / Multiple Myeloma (MM)1
1, 2Unknown StatusTreatmentChronic HIV-infection1
1, 2Unknown StatusTreatmentMultiple Myeloma (MM)1
1, 2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentAdult Alveolar Soft-part Sarcoma / Adult Angiosarcoma / Adult Epithelioid Sarcoma / Adult Extraskeletal Chondrosarcoma / Adult Extraskeletal Osteosarcoma / Adult Fibrosarcoma / Adult Leiomyosarcoma / Adult Liposarcoma / Adult Malignant Fibrous Histiocytoma / Adult Malignant Hemangiopericytoma / Adult Malignant Mesenchymoma / Adult Neurofibrosarcoma / Adult Rhabdomyosarcoma / Adult Synovial Sarcoma / Gastrointestinal Stromal Tumors / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Adult Soft Tissue Sarcoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2Active Not RecruitingTreatmentCutaneous T Cell Lymphomas (CTCL) / Peripheral T Cell Lymphoma (PTCL)1
2Active Not RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)2
2CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Promyelocytic Leukemia (M3) / Recurrent Adult Acute Myeloid Leukemia1
2CompletedTreatmentCancers / Malignant Lymphomas1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentCutaneous T-Cell Lymphoma (CTCL)1
2CompletedTreatmentDS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Recurrent Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentMale Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMetastases / Prostate Cancer1
2CompletedTreatmentNeoplasms Metastasis / Renal Cell Adenocarcinoma1
2CompletedTreatmentProstatic Neoplasms / Renal Cell Adenocarcinoma1
2CompletedTreatmentRecurrent Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Thyroid Cancer / Stage IV Follicular Thyroid Cancer / Stage IV Papillary Thyroid Cancer1
2CompletedTreatmentStage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Oropharynx1
2RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV)2
2TerminatedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinoma of the Stomach / Recurrent Esophageal Cancer / Recurrent Gastric Cancer1
2TerminatedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2TerminatedTreatmentGastrinoma / Glucagonoma / Insulinoma / Metastatic Gastrointestinal Carcinoid Tumor / Pancreatic Polypeptide Tumor / Pulmonary Carcinoid Tumor / Recurrent Gastrointestinal Carcinoid Tumor / Recurrent Islet Cell Carcinoma / Regional Gastrointestinal Carcinoid Tumor / Somatostatinoma1
2TerminatedTreatmentMalignant Melanoma / Melanoma1
2TerminatedTreatmentMultiple Myeloma (MM)1
2TerminatedTreatmentPrimary Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2TerminatedTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Mantle Cell Lymphoma1
2TerminatedTreatmentRecurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Small Lymphocytic Lymphoma1
2WithdrawnTreatmentCancer, Ovarian1
3Active Not RecruitingTreatmentPeripheral T-cell lymphoma unspecified refractory / Relapsed Peripheral T-Cell Lymphoma1
3RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
Not AvailableCompletedNot AvailableCutaneous T-Cell Lymphoma (CTCL)1
Not AvailableTerminatedSupportive CareGraft Versus Host Disease (GVHD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit
Kit; powder, for solutionIntravenous10 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7611724No2001-08-222021-08-22Us
US7608280No2001-08-222021-08-22Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.021 mg/mLALOGPS
logP3.05ALOGPS
logP-0.53ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)-9.5ChemAxon
pKa (Strongest Basic)14.95ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area156.66 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity144.17 m3·mol-1ChemAxon
Polarizability54.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cyclic depsipeptides. These are natural or synthetic compounds having sequences of amino and hydroxy carboxylic acid residues (usually α-amino and α-hydroxy acids) connected in a ring. The residues are commonly but not necessarily regularly alternating.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Peptidomimetics
Sub Class
Depsipeptides
Direct Parent
Cyclic depsipeptides
Alternative Parents
Macrolide lactams / Alpha amino acid esters / Macrolides and analogues / Macrolactams / Secondary carboxylic acid amides / Carboxylic acid esters / Organic disulfides / Lactones / Lactams / Oxacyclic compounds
show 7 more
Substituents
Cyclic depsipeptide / Macrolide lactam / Alpha-amino acid ester / Macrolactam / Macrolide / Alpha-amino acid or derivatives / Carboxamide group / Carboxylic acid ester / Lactam / Lactone
show 16 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Inhibitor
General Function
Transcription regulatory region sequence-specific dna binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC1
Uniprot ID
Q13547
Uniprot Name
Histone deacetylase 1
Molecular Weight
55102.615 Da
References
  1. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011 Aug;64(8):525-31. doi: 10.1038/ja.2011.35. Epub 2011 May 18. [PubMed:21587264]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Inhibitor
General Function
Transcription factor binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC2
Uniprot ID
Q92769
Uniprot Name
Histone deacetylase 2
Molecular Weight
55363.855 Da
References
  1. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011 Aug;64(8):525-31. doi: 10.1038/ja.2011.35. Epub 2011 May 18. [PubMed:21587264]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC4
Uniprot ID
P56524
Uniprot Name
Histone deacetylase 4
Molecular Weight
119038.875 Da
References
  1. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011 Aug;64(8):525-31. doi: 10.1038/ja.2011.35. Epub 2011 May 18. [PubMed:21587264]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
Gene Name
HDAC6
Uniprot ID
Q9UBN7
Uniprot Name
Histone deacetylase 6
Molecular Weight
131418.19 Da
References
  1. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH: Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot (Tokyo). 2011 Aug;64(8):525-31. doi: 10.1038/ja.2011.35. Epub 2011 May 18. [PubMed:21587264]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Xiao JJ, Foraker AB, Swaan PW, Liu S, Huang Y, Dai Z, Chen J, Sadee W, Byrd J, Marcucci G, Chan KK: Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther. 2005 Apr;313(1):268-76. Epub 2005 Jan 5. [PubMed:15634944]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Iwamoto FM, Lamborn KR, Kuhn JG, Wen PY, Yung WK, Gilbert MR, Chang SM, Lieberman FS, Prados MD, Fine HA: A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May;13(5):509-16. doi: 10.1093/neuonc/nor017. Epub 2011 Mar 3. [PubMed:21377994]
  2. Shiraga T, Tozuka Z, Ishimura R, Kawamura A, Kagayama A: Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull. 2005 Jan;28(1):124-9. [PubMed:15635176]
  3. Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD: Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503. doi: 10.1158/1078-0432.CCR-08-1215. [PubMed:19228751]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Shiraga T, Tozuka Z, Ishimura R, Kawamura A, Kagayama A: Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull. 2005 Jan;28(1):124-9. [PubMed:15635176]
  2. Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD: Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503. doi: 10.1158/1078-0432.CCR-08-1215. [PubMed:19228751]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD: Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503. doi: 10.1158/1078-0432.CCR-08-1215. [PubMed:19228751]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotre...
Gene Name
SLCO1B3
Uniprot ID
Q9NPD5
Uniprot Name
Solute carrier organic anion transporter family member 1B3
Molecular Weight
77402.175 Da
References
  1. Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, Price DK, Frye R, Piekarz RL, Bates SE, Figg WD: Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503. doi: 10.1158/1078-0432.CCR-08-1215. [PubMed:19228751]

Drug created on March 19, 2008 10:15 / Updated on November 14, 2017 08:10